CASP1 and diabetic kidney disease: In diabetic nephropathy models, both in vivo and in vitro, MCC950 attenuates glomerular basement membrane thickening, podocyte injury, and renal fibrosis by suppressing the NLRP3/caspase-1/IL-1β signaling axis (143, 260).